Kane Biotech Announces New Private Placement Offering

Core Viewpoint - Kane Biotech Inc. is planning a non-brokered private placement offering of up to 16 million common shares at a price of $0.05 per share, aiming for gross proceeds of up to $800,000 [1][2]. Group 1: Offering Details - The net proceeds from the offering will be allocated for working capital and general corporate purposes [2]. - The closing of the offering is anticipated to occur around December 17, 2025 [2]. - All shares issued will be subject to a hold period of four months and one day from the issuance date [2]. Group 2: Company Overview - Kane Biotech is focused on developing innovative wound care treatments that target biofilms, which contribute to antibiotic resistance in wounds [4]. - The company's products, including revyve Antimicrobial Wound Gel and revyve Antimicrobial Wound Gel Spray, have received US FDA 510(k) clearance and Health Canada approval [4].